title: The adjunctive use of perfluoroperhydrophenanthrene (Vitreon) in diabetic vitrectomy.
abstract: OBJECTIVE
  To evaluate the utility and efficacy of perfluoroperhydrophenanthrene in the management of retinal detachments secondary to severe proliferative diabetic retinopathy.
  
  
  METHODS
  Forty consecutive patients with proliferative diabetic retinopathy and retinal detachments were entered into the study at nine participating clinical centers. Perfluoroperhydrophenanthrene (Vitreon) was used as an adjunct to pars plana vitrectomy and membranectomy.
  
  
  RESULTS
  Preoperative diagnoses included combined traction and rhegmatogenous retinal detachments in 23 eyes (57.5%), traction retinal detachments in 13 eyes (32.5%), and recurrent rhegmatogenous retinal detachments in 4 eyes (10). Vitreous hemorrhage was present in 17 eyes (42.5%). Preoperative visual acuity ranged from light perception or hand motion in 28 eyes (70%) to 5/200 or greater in 12 eyes (30%). Vitreon was primarily used to flatten the retina following relaxing retinotomy in 12 eyes (30%), to displace subretinal fluid in a posterior-to-anterior direction without performing a drainage retinotomy in 15 eyes (37.5%), and to manage intraoperative complications such as iatrogenic tears in 8 (20%) and retinal dialysis in 5 eyes (12.5%). The retina flattened intraoperatively in all cases, facilitating administration of laser photocoagulation. Patients were followed for a minimum of six months (mean 13.2 months). At last follow up, the macula remained attached in 37 eyes (92.5%), including 31 (77.5%) in which the retina was totally attached. The retina remained detached in 3 eyes (7.5%). Visual acuity improved postoperatively in 20 patients (50%), was unchanged in 13 patients (32.5%), and worsened in 7 patients (17.5%).
  
  
  CONCLUSIONS
  Perfluoroperhydrophenanthrene is a useful and effective intraoperative tool for the management of complex retinal detachments secondary to severe proliferative diabetic retinopathy.
authors.affiliation: LSU Eye Center, Louisiana State University Medical Center School of Medicine, New Orleans 70112-2234, USA.
authors.forename: H
authors.initials: H
authors.lastname: Wafapoor
authors.forename: P J
authors.initials: PJ
authors.lastname: Kertes
authors.forename: G C
authors.initials: GC
authors.lastname: Navarro
authors.forename: G A
authors.initials: GA
authors.lastname: Peyman
authors.forename: S
authors.initials: S
authors.lastname: Meffert
authors.forename: G J
authors.initials: GJ
authors.lastname: Ganiban
authors.forename: S
authors.initials: S
authors.lastname: Vierling
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D017024:Chemotherapy, Adjuvant; D003930:Diabetic Retinopathy / Q000150:complications*; D005260:Female; D005466:Fluorocarbons / Q000627:therapeutic use*; D006801:Humans; D017075:Laser Coagulation; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011446:Prospective Studies; D012008:Recurrence; D012163:Retinal Detachment / Q000209:etiology / Q000601:surgery*; D014792:Visual Acuity; D014821:Vitrectomy; D014823:Vitreous Hemorrhage / Q000209:etiology / Q000473:pathology / Q000601:surgery
chemical_list: D005466:Fluorocarbons; C047722:perfluorophenanthrene